| ID | 114802 |
| 著者 | |
| キーワード | Hyperuricemia
Gout
Chronic kidney disease (CKD)
Febuxostat
Allopurinol
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Hyperuricemia and gout have been important diseases, which have close relationship with metabolic syndrome, cardiovascular, and chronic kidney diseases. Oral medicine for treatment includes febuxostat and allopurinol. Both agents have been compared as urate-lowering therapy for the influence of cardiovascular and renal risk factors. Some papers showed no difference for the major adverse cardiac events (MACEs) between both agents. However, there have been controversies concerning the benefit and risk of them. Further evaluation would be necessary and expected for future research.
|
| 掲載誌名 |
Journal of Diabetes, Obesity & Metabolism
|
| 出版者 | Yumed Text
|
| 巻 | 3
|
| 号 | 1
|
| 開始ページ | e104
|
| 発行日 | 2020-03-10
|
| 権利情報 | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License(https://creativecommons.org/licenses/by-nc-sa/4.0/).
|
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
